The oral drug technology developer, which is backed by corporates including Alphabet, Novartis and AstraZeneca, has now raised $100m in total.

Rani Therapeutics, a US-based drug delivery technology developer backed by internet and technology group Alphabet and pharmaceutical firms Novartis and AstraZeneca, has raised $39m in new funding, CNBC has reported.

The participants in the latest round were not disclosed, but CNBC described all three corporates as among Rani’s “current and existing investors”.

Rani is working on a system that will enable large-drug molecules such as peptides, proteins and antibodies to be delivered orally rather than through injections. The technology was…